BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23821185)

  • 1. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.
    Bridges TM; Rook JM; Noetzel MJ; Morrison RD; Zhou Y; Gogliotti RD; Vinson PN; Xiang Z; Jones CK; Niswender CM; Lindsley CW; Stauffer SR; Conn PJ; Daniels JS
    Drug Metab Dispos; 2013 Sep; 41(9):1703-14. PubMed ID: 23821185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
    Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
    Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
    Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).
    Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR
    J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
    Noetzel MJ; Gregory KJ; Vinson PN; Manka JT; Stauffer SR; Lindsley CW; Niswender CM; Xiang Z; Conn PJ
    Mol Pharmacol; 2013 Apr; 83(4):835-47. PubMed ID: 23348500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
    Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
    Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
    ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate receptor 5 (mGlu
    Hellyer SD; Albold S; Sengmany K; Singh J; Leach K; Gregory KJ
    J Neurochem; 2019 Nov; 151(3):301-315. PubMed ID: 31376155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
    Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
    Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
    Gregory KJ; Herman EJ; Ramsey AJ; Hammond AS; Byun NE; Stauffer SR; Manka JT; Jadhav S; Bridges TM; Weaver CD; Niswender CM; Steckler T; Drinkenburg WH; Ahnaou A; Lavreysen H; Macdonald GJ; Bartolomé JM; Mackie C; Hrupka BJ; Caron MG; Daigle TL; Lindsley CW; Conn PJ; Jones CK
    J Pharmacol Exp Ther; 2013 Nov; 347(2):438-57. PubMed ID: 23965381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism.
    Sengmany K; Hellyer SD; Christopoulos A; Lapinsky DJ; Leach K; Gregory KJ
    Biochem Pharmacol; 2020 Jul; 177():114011. PubMed ID: 32380090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
    Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
    Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site.
    Hellyer SD; Sengmany K; Keller AN; Christopoulos A; Leach K; Gregory KJ
    Biochem Pharmacol; 2020 Jul; 177():114013. PubMed ID: 32389635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
    Rook JM; Xiang Z; Lv X; Ghoshal A; Dickerson JW; Bridges TM; Johnson KA; Foster DJ; Gregory KJ; Vinson PN; Thompson AD; Byun N; Collier RL; Bubser M; Nedelcovych MT; Gould RW; Stauffer SR; Daniels JS; Niswender CM; Lavreysen H; Mackie C; Conde-Ceide S; Alcazar J; Bartolomé-Nebreda JM; Macdonald GJ; Talpos JC; Steckler T; Jones CK; Lindsley CW; Conn PJ
    Neuron; 2015 May; 86(4):1029-1040. PubMed ID: 25937172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.
    Rook JM; Tantawy MN; Ansari MS; Felts AS; Stauffer SR; Emmitte KA; Kessler RM; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Neuropsychopharmacology; 2015 Feb; 40(3):755-65. PubMed ID: 25241804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
    Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
    J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
    Liu F; Grauer S; Kelley C; Navarra R; Graf R; Zhang G; Atkinson PJ; Popiolek M; Wantuch C; Khawaja X; Smith D; Olsen M; Kouranova E; Lai M; Pruthi F; Pulicicchio C; Day M; Gilbert A; Pausch MH; Brandon NJ; Beyer CE; Comery TA; Logue S; Rosenzweig-Lipson S; Marquis KL
    J Pharmacol Exp Ther; 2008 Dec; 327(3):827-39. PubMed ID: 18753411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
    Rodriguez AL; Grier MD; Jones CK; Herman EJ; Kane AS; Smith RL; Williams R; Zhou Y; Marlo JE; Days EL; Blatt TN; Jadhav S; Menon UN; Vinson PN; Rook JM; Stauffer SR; Niswender CM; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2010 Dec; 78(6):1105-23. PubMed ID: 20923853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of mGlu
    Ghoshal A; Moran SP; Dickerson JW; Joffe ME; Grueter BA; Xiang Z; Lindsley CW; Rook JM; Conn PJ
    ACS Chem Neurosci; 2017 Oct; 8(10):2254-2265. PubMed ID: 28679049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.